Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain LOXO message board posts where the ticker symbol LOXO has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest LOXO SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, items 7.01 and 9.01
Acc-no: 0001104659-17-071505 (34 Act)  Size: 57 KB
2017-12-04 001-36562
171235502
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-044233 Size: 12 KB
2017-11-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-044232 Size: 22 KB
2017-11-29
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-044229 Size: 27 KB
2017-11-29
SC 13D/A  Documents [Amend] General statement of acquisition of beneficial ownership
Acc-no: 0000950142-17-002112 (34 Act)  Size: 151 KB
2017-11-28 005-88267
171225684
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000950142-17-002107 Size: 29 KB
2017-11-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-043871 Size: 8 KB
2017-11-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000947871-17-000970 Size: 6 KB
2017-11-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000947871-17-000969 Size: 9 KB
2017-11-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001140361-17-043697 Size: 9 KB
2017-11-22
More LOXO SEC Filings


Related news from
Mon, 04 Dec 2017
11:48:00 +0000
Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers
WHIPPANY, N.J., Dec. 4, 2017 /PRNewswire/ -- Bayer and Loxo Oncology, Inc., (LOXO), today announced updated clinical data from the larotrectinib (LOXO-101) pediatric Phase I SCOUT trial (NCT02637687). Bayer and Loxo Oncology are jointly developing larotrectinib, an investigational compound being studied for the treatment of patients with cancers harboring tropomyosin receptor kinase (TRK) gene fusions, which are genetic alterations present across a wide range of tumors resulting in uncontrolled TRK signaling and tumor growth.
Mon, 04 Dec 2017
11:45:00 +0000
Loxo Oncology Announces Updated Larotrectinib Pediatric Clinical Trial Data Demonstrating Continued Durability of Response in TRK Fusion Cancers
–94 Percent of All Pediatric Patients Remain on Larotrectinib or Received Surgery with Curative Intent–. –Larotrectinib Demonstrates Central Nervous System Activity with First-Ever TRK Fusion Glioblastoma ...
Thu, 30 Nov 2017
20:42:05 +0000
Loxo Oncology, Inc. Fundamental Analysis : November 30, 2017
Categories: Yahoo FinanceGet free summary analysis Company Profile Loxo Oncology, Inc. is a biopharmaceutical company, which develops small molecule therapeutics for the treatment of cancer. Its pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. The company was founded ... Read more <b>(Read more...)</b>
Thu, 30 Nov 2017
13:05:02 +0000
See what the IHS Markit Score report has to say about Loxo Oncology Inc.
Loxo Oncology Inc NASDAQ NMS:LOXO
Wed, 22 Nov 2017
00:10:00 +0000
Cramer's lightning round: Don't sell Deutsche Bank. It's ...
Jim Cramer flew through his take on callers' favorite stocks, including that of one high-profile bank.
Tue, 21 Nov 2017
11:01:00 +0000
Fighting Cancer One Patient At A Time
Companies large and small are competing to attack rare genetic mutations that cause cancer. The reason? Great science and high drug prices. The result? Soaring stock prices.
Sun, 19 Nov 2017
16:43:00 +0000
3 Biotech Stocks to Be Thankful for This Year
If you notice a relative who can't stop grinning at the Thanksgiving dinner table, they're probably holding shares of these biotech stocks.
Sat, 18 Nov 2017
17:35:00 +0000
Is Loxo Oncology's Deal With Bayer Bad News?
Investors appear discouraged by the company's decision to license its lead product.
Thu, 16 Nov 2017
12:13:12 +0000
Pharma Stock Roundup: FDA Nod for AstraZeneca Severe Asthma Drug, Bayer Signs Deal with Loxo
Key highlights this week include the FDA approval of AstraZeneca's (AZN) severe asthma drug and Bayer's collaboration with Loxo for cancer.
Thu, 16 Nov 2017
12:10:00 +0000
Corporate News Blog - Loxo Oncology Collaborates with Bayer to Develop and Commercialize Larotrectinib and LOXO-195
Research Desk Line-up: Acceleron Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
Wed, 15 Nov 2017
13:16:01 +0000
Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer
Regulatory actions and licensing and collaboration agreements were the key highlights this week with companies like Loxo Oncology (LOXO) remaining in the limelight.
Tue, 14 Nov 2017
21:18:14 +0000
Biotechs Sell Off In Droves — Are Investors Seeking Mergers?
Loxo's deal with Bayer had a bigger impact on the biotech sector than you'd expect, an industry observer said.
Tue, 14 Nov 2017
21:13:40 +0000
This Cancer Biotech Is Falling On Its $1.55 Billion Bayer Deal
Loxo toppled Tuesday after agreeing to codevelop two cancer therapies with drug firm Bayer.
Tue, 14 Nov 2017
20:30:00 +0000
Bayer Bets Big on a Tiny Cancer Drug Up-and-Comer
The global pharmaceutical giant has signed a deal that could be worth more than $1.5 billion to this clinical-stage cancer drug developer.
Tue, 14 Nov 2017
19:12:45 +0000
Loxo's Good Deed Goes Punished
Splitting sales with Bayer won't kill its takeover chances.
Tue, 14 Nov 2017
17:10:22 +0000
Loxo signs lucrative cancer drug deal with Bayer, but shares fall
Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover. Loxo caused a great deal of excitement at last year's biggest cancer meeting when its larotrectinib, which targets a specific genetic defect, led to significant tumor shrinkage in three quarters of patients with more than a dozen different tumor types, including several complete remissions . The deal, which includes Loxo's follow-up drug LOXO-195, gives Bayer entry into the fledgling field of drugs that attack cancer based on genetics rather than the organ where the disease originates.
Tue, 14 Nov 2017
14:29:09 +0000
What Is Loxo Oncology Inc’s (LOXO) Share Price Doing?
Loxo Oncology Inc (NASDAQ:LOXO), a biotechnology company based in United States, saw a decent share price growth in the teens level on the NasdaqGM over the last few months. WithRead More...
Tue, 14 Nov 2017
14:10:49 +0000
Loxo, Bayer to co-develop cancer drugs in up to $1.55 bln deal
Loxo Oncology will collaborate with Germany's Bayer to develop and commercialize two of its cancer therapies, the companies said, in a deal that could bring the U.S. drug developer up to $1.55 billion over the next few years. Loxo will receive $400 million upfront from Bayer and the two companies will split development costs and U.S. profits equally.
Tue, 14 Nov 2017
13:03:00 +0000
Loxo Sells Bayer Rights To Rare Cancer Drug For More Than $1 Billion
Bayer will pay $400 million -- and up to $1.15 million more in milestones tied to regulatory approvals and sales -- for commercial rights to a rare cancer drug being developed by Loxo Oncology, a small Stamford, Conn.-based biotechnology firm.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "No friend, no book, no broker, no advisor, no expert has ever provided a tenth what I am able to find here. The best money I have EVER spent, is for membership." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2017, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards